CN101605808A - 人巨细胞病毒(hcmv)的重组抗原 - Google Patents

人巨细胞病毒(hcmv)的重组抗原 Download PDF

Info

Publication number
CN101605808A
CN101605808A CNA2008800045081A CN200880004508A CN101605808A CN 101605808 A CN101605808 A CN 101605808A CN A2008800045081 A CNA2008800045081 A CN A2008800045081A CN 200880004508 A CN200880004508 A CN 200880004508A CN 101605808 A CN101605808 A CN 101605808A
Authority
CN
China
Prior art keywords
ser
pro
thr
ala
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2008800045081A
Other languages
English (en)
Chinese (zh)
Inventor
N·加尔加诺
E·贝赫托
A·斯帕东尼
F·德帕奥利斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CN101605808A publication Critical patent/CN101605808A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/04—Varicella-zoster virus
    • G01N2333/045—Cytomegalovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
CNA2008800045081A 2007-02-07 2008-02-05 人巨细胞病毒(hcmv)的重组抗原 Pending CN101605808A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07101864 2007-02-07
EP07101864.2 2007-02-07

Publications (1)

Publication Number Publication Date
CN101605808A true CN101605808A (zh) 2009-12-16

Family

ID=38229391

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2008800045081A Pending CN101605808A (zh) 2007-02-07 2008-02-05 人巨细胞病毒(hcmv)的重组抗原

Country Status (13)

Country Link
US (1) US20100068229A1 (enExample)
EP (1) EP2114991A1 (enExample)
JP (1) JP2010517544A (enExample)
KR (1) KR20090126256A (enExample)
CN (1) CN101605808A (enExample)
AU (1) AU2008213356A1 (enExample)
BR (1) BRPI0807095A2 (enExample)
CA (1) CA2677455A1 (enExample)
EA (1) EA200970731A1 (enExample)
IL (1) IL200187A0 (enExample)
MX (1) MX2009008248A (enExample)
SG (1) SG178761A1 (enExample)
WO (1) WO2008095677A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102816246A (zh) * 2012-09-04 2012-12-12 成都蓉生药业有限责任公司 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途
CN103003694A (zh) * 2010-07-07 2013-03-27 富士瑞必欧株式会社 人巨细胞病毒感染的检测方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5833565B2 (ja) 2009-12-23 2015-12-16 ４−アンティボディ・アクチェンゲゼルシャフト４−Ａｎｔｉｂｏｄｙ Ａｇ ヒトサイトメガロウイルスに対する結合メンバー
US20130288389A1 (en) * 2011-01-18 2013-10-31 Prionics Ag Methods for amplification and detection of prions
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2019020480A1 (en) * 2017-07-24 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL60184A (en) * 1979-05-31 1984-05-31 Schering Ag Process for the specific cleavage of protein sequences from proteins
RU2023448C1 (ru) * 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
CA2050425A1 (en) * 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
EP2156845A1 (en) * 1992-05-23 2010-02-24 GlaxoSmithKline Biologicals SA Combined vaccines comprising hepatitis B surface antigen and other antigens
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US5846806A (en) 1994-07-29 1998-12-08 American Cyanamid Company Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
AU735981B2 (en) * 1996-07-12 2001-07-19 Akzo Nobel N.V. Peptide reagent for the detection of human cytomegalovirus (CMV)
US6306404B1 (en) * 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
WO2003010198A1 (en) 2001-07-26 2003-02-06 Kenton Srl Identification of specific tumour antigens by selection of cdna libraries with sera and use of said antigens in diagnostic techniques

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103003694A (zh) * 2010-07-07 2013-03-27 富士瑞必欧株式会社 人巨细胞病毒感染的检测方法
CN102816246A (zh) * 2012-09-04 2012-12-12 成都蓉生药业有限责任公司 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途
CN102816246B (zh) * 2012-09-04 2014-07-23 成都蓉生药业有限责任公司 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途

Also Published As

Publication number Publication date
IL200187A0 (en) 2010-04-15
WO2008095677A1 (en) 2008-08-14
EA200970731A1 (ru) 2010-02-26
BRPI0807095A2 (pt) 2014-04-22
SG178761A1 (en) 2012-03-29
JP2010517544A (ja) 2010-05-27
KR20090126256A (ko) 2009-12-08
EP2114991A1 (en) 2009-11-11
CA2677455A1 (en) 2008-08-14
MX2009008248A (es) 2009-08-12
US20100068229A1 (en) 2010-03-18
AU2008213356A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
CN113292640A (zh) 一种产生广谱交叉中和活性的重组新型冠状病毒rbd三聚体蛋白疫苗、其制备方法和应用
CN101605808A (zh) 人巨细胞病毒(hcmv)的重组抗原
JP4612071B2 (ja) エプスタイン−バールウイルスペプチド及び該ペプチドに対する抗体
CN112125961B (zh) 牛病毒性腹泻-牛传染性鼻气管炎二联亚单位融合疫苗及其鉴定方法
IL184845A (en) Chimeric recombinant antigen containing the fusion of at least three different antigenic regions of toxoplasma gondii, nucleotide sequence encoding the same, pharmaceutical composition comprising the same, process for its production and uses of the same in the preparation of diagnostic compositions and medicaments
US6322794B1 (en) Seroreactive epitopes on proteins of human papillomavirus (HPV) 18
EA022788B1 (ru) Новые терапевтические и диагностические средства
JPH09500009A (ja) Ｃ型肝炎ウイルス４、５及び６型
WO2002040681A1 (en) The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
US7303913B2 (en) Rapid diagnostic methods of Peste des Petits Ruminants using recombinant nucleocapsid protein expressed in insect cells and monoclonal antibody
JP2000514300A (ja) ヒトサイトメガロウイルス（ｃｍｖ）を検出するためのペプチド試薬
WO2023066396A1 (zh) 靶向识别抗新冠病毒中和抗体N-IgY-pAbs的核心氨基酸序列组及应用
CN117043177A (zh) 非洲猪瘟diva免疫测定
WO2022036337A1 (en) Compositions and methods for recombinant polypeptide mimicking sars-cov-2 nucleocapsid protein (np)
JP2008520210A (ja) Ｈｃｖｆタンパク質及びその使用
US5773235A (en) Equine arteritis virus peptides; antibodies and their use in a diagnostic test
JPH09504685A (ja) Ｈａｒｄｓウイルスの組換えｄｎａ抗原を製造する分子クローン
HK1135116A (en) Recombinant antigens of human cytomegalovirus (hcmv)
CN113493494B (zh) Eb病毒balf3蛋白的抗原表位
US20140004141A1 (en) Methods And Compositions Of Protein Antigens For The Diagnosis And Treatment Of Toxoplasma Gondii Infections And Toxoplasmosis
CN113493495B (zh) Eb病毒balf4蛋白的抗原表位
JP2016503011A (ja) レプトスピラ症の診断および処置のための方法およびタンパク質抗原の組成物
JP2003043044A (ja) 抗体捕捉法による抗体の免疫学的測定方法
JPH0475583A (ja) ハイブリドーマ系細胞とその細胞により産生されるモノクローナル抗体
HK1071436B (en) Compositions and methods for diagnosing and preventing severe acute respiratory syndrome (sars)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1135116

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20091216

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1135116

Country of ref document: HK